South Korea Prescription drugs: key facts

Last updated 2026-11-12 · 11 sourced answers from KIRA RESEARCH reports and field research. Every figure shows its year and source.

Key players

Who makes the heart and cholesterol generics sold in Korea after patent expiry?

Most sellers do not own a factory; contract manufacturers make the product, and the winner is whoever carries it into clinics, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Channels and distribution

Which customers do Korean makers of heart and cholesterol generics target first?

Clinics: domestic makers run clinic-heavy sales forces, with several clinic reps for every hospital rep, as their main weapon against the originator, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Do clinical trials at top university hospitals help a heart drug win hospital listings in Korea?

Yes: trial sites are the natural first hospital to list the drug, though top hospitals run several competing trials, which raises trial costs, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Is national reimbursement listing enough to sell a heart drug to Korean hospitals?

No: each hospital's drug committee is a separate gate where price matters, so firms without strong hospital coverage usually find a partner, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Pricing

Do Korean drug-pricing officials examine expensive generic price filings more closely?

Officials rely largely on submitted documents: moderately priced filings pass easily, while expensive ones are examined hard, so most makers price modestly at listing, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Regulation

How have promotion rules changed the way Korean heart-drug makers sell to doctors?

After official warnings over illegal support, firms cut sponsorship and rely on clinical data, symposia and bundles with their other cardiovascular drugs, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Does winning a patent challenge give a generic heart drug a launch date in Korea?

Practitioners say a court win is a queue ticket, not a launch date; Entresto challengers won, yet approvals stand at 0 (Dailypharm, 20 Jan 2026), as cited in KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Market entry

What should a Japanese or Chinese maker do to enter Korea's heart-drug generic market?

Enter early with a partner that has a clinic sales force, or bring what the crowd cannot copy fast: a combination, new strength or clinical data, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

How the trade works

In Korea, does the first generic heart or cholesterol drug to launch win most of the share?

Yes, practitioners expect the first entrant to win most share; later entrants watch its launch numbers before setting price, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

How quickly do clinic doctors switch patients to a newly listed heart drug in Korea?

Doctors switch patients in the first month after listing, and stable heart-pill patients do not usually switch twice, so early listings often keep prescriptions, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

How do original heart-drug brands defend their share against generic entrants in Korea?

They bring outcome data, new strengths or indications and cut price selectively where it hurts most, giving doctors a reason to stay, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).

Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Who decides

Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.

Who specifies

  • Each hospital has its own drug committee, a separate listing gate after national reimbursement, and price matters there as well. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia)

Who buys and pays

  • Most blood-pressure and cholesterol patients get their monthly prescription at a neighbourhood clinic, so the clinic doctor is the buyer a new product must win. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia)
  • Contract sales organizations carry much of the outsourced sales effort, and high commissions prompt questions about what they are paid to do. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia)

Who carries the risk

No field statement yet

How the trade works

Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.